Absolute monocyte count（AEC）may be one of the most optimal peripheral
blood markers to identify risk of immune-related events in advanced
malignant tumors treated with PD-1/PD-L1 inhibitors.
Purpose To investigate the predictive value of serum biomarkers such as
AEC、Neutrophil- lymphocyte ratio (NLR) and platelets - lymphocyte
ratio(PLR) on immune-related adverse events (irAEs) during the
PD-1/PD-L1 inhibitors treatment in advanced malignant tumors. Methods We
retrospectively analyzed 95 advanced cancer patients treated with
PD-1/PD-L1 inhibitor from January 1, 2017 to May 1, 2020 in our cancer
center. Then, the associations between irAEs and PD-1/PD-L1 inhibitors
respond was analyzed and the predictive value of serum biomarkers on
irAEs occurrence risk was evaluated. Results The incidence of irAEs was
55.8%. There were no statistically significant differences between the
irAEs group and the no-irAEs group in Objective response rate (ORR) and
Disease control rate (DCR), but the Landmark analysis showed that the
irAEs group had better survival after 120 days compared with the
no-irAEs group. The incidence of irAEs in the high-AEC and low-NLR
groups was greater than that in the low-AEC and high-NLR
groups.Univariate logistic analysis results showed that low-NLR, ECOG
(0-1) and High-AEC were risk factors for irAEs. However, multivariate
logistic analysis not only shows that AEC is an independent factor of
irAEs , but also suggests that good ECOG may be more prone to irAEs .
Conclusions IrAEs may show a survival benefit to a certain extent.
Baseline AEC is a strong predictor of irAEs in the treatment of